Use of copeptin for rapid rule-out of acute myocardial infarction

ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.

Original languageEnglish (US)
Pages (from-to)570-576
Number of pages7
JournalEuropean heart journal. Acute cardiovascular care
Volume7
Issue number6
DOIs
StatePublished - Sep 1 2018

Fingerprint

Troponin
Myocardial Infarction
copeptins

Keywords

  • Acute myocardial infarction
  • diagnosis
  • rule-out

ASJC Scopus subject areas

  • Medicine(all)

Cite this

ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association (2018). Use of copeptin for rapid rule-out of acute myocardial infarction. European heart journal. Acute cardiovascular care, 7(6), 570-576. https://doi.org/10.1177/2048872617710791

Use of copeptin for rapid rule-out of acute myocardial infarction. / ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association.

In: European heart journal. Acute cardiovascular care, Vol. 7, No. 6, 01.09.2018, p. 570-576.

Research output: Contribution to journalReview article

ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association 2018, 'Use of copeptin for rapid rule-out of acute myocardial infarction', European heart journal. Acute cardiovascular care, vol. 7, no. 6, pp. 570-576. https://doi.org/10.1177/2048872617710791
ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association. Use of copeptin for rapid rule-out of acute myocardial infarction. European heart journal. Acute cardiovascular care. 2018 Sep 1;7(6):570-576. https://doi.org/10.1177/2048872617710791
ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association. / Use of copeptin for rapid rule-out of acute myocardial infarction. In: European heart journal. Acute cardiovascular care. 2018 ; Vol. 7, No. 6. pp. 570-576.
@article{b65ef33dd2df466991e384ddfa6d59ae,
title = "Use of copeptin for rapid rule-out of acute myocardial infarction",
abstract = "Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.",
keywords = "Acute myocardial infarction, diagnosis, rule-out",
author = "{ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association} and Christian Mueller and Martin M{\"o}ckel and Evangelos Giannitsis and Kurt Huber and Johannes Mair and Mario Plebani and Kristian Thygesen and Jaffe, {Allan S} and Bertil Lindahl",
year = "2018",
month = "9",
day = "1",
doi = "10.1177/2048872617710791",
language = "English (US)",
volume = "7",
pages = "570--576",
journal = "European Heart Journal: Acute Cardiovascular Care",
issn = "2048-8726",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Use of copeptin for rapid rule-out of acute myocardial infarction

AU - ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association

AU - Mueller, Christian

AU - Möckel, Martin

AU - Giannitsis, Evangelos

AU - Huber, Kurt

AU - Mair, Johannes

AU - Plebani, Mario

AU - Thygesen, Kristian

AU - Jaffe, Allan S

AU - Lindahl, Bertil

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.

AB - Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.

KW - Acute myocardial infarction

KW - diagnosis

KW - rule-out

UR - http://www.scopus.com/inward/record.url?scp=85028522633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028522633&partnerID=8YFLogxK

U2 - 10.1177/2048872617710791

DO - 10.1177/2048872617710791

M3 - Review article

VL - 7

SP - 570

EP - 576

JO - European Heart Journal: Acute Cardiovascular Care

JF - European Heart Journal: Acute Cardiovascular Care

SN - 2048-8726

IS - 6

ER -